Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: macker who wrote (1172)	6/18/1998 12:20:00 PM
From: RocketMan	Respond to of 5402

Well, macker, I defer to your knowledge of biotechnology, since you are in the medical field. So this is even bigger than I thought!

To: macker who wrote (1172)	6/18/1998 12:26:00 PM
From: Jim B	Respond to of 5402

Macker, very good points.. I think not even those of us who have done our DD have any clue as to how big this could eventually turn out to be.. glad to be aboard with you! jim

To: macker who wrote (1172)	6/18/1998 12:57:00 PM
From: Gwolf	Read Replies (1) \| Respond to of 5402

" What price would you expect as a buyout offer ?".................. If you had a product that could produce $20 billion in revenues per YEAR, what would you be willing to sell it for? Would you ask for 5 years revenues, 3 years, 1 year, what would you ask for. Personally I wouldn't sell, however this is a public company and somebody like a Baxter can just come in and buy everything that the principals don't own. They can then put themselves on the board and make your life miserable until you sell. So what do you do, you arrive at a price, sell out, stay with the company as it's president and enjoy life. So we're back to the sales price. Any buyout will probably come long before final FDA approval for humans takes place. My guess would be closer to the completion of the animal trials, so you probably won't be able to command the same price as if you had full FDA approval. Let's be conservative and say you only get 1 years worth of revenues, that's $20 billion. $20 billion divided by 21 million shares outstanding equals $952 per share. You say no way.....too much. Okay let's try just 1 months worth of revenues. 1 months worth of revenues is $1.6 billion divided by 21 million shares that's $79.33 per share. Again you say no way. What do you want to try for 2 weeks worth of revenues that would be $39.66 per share for 2 weeks worth of a $20 billion dollar market. At some point don't you have to say, hey wait a minute your trying to steal the company from me. I don't know what the company would sell at right this minute. I believe that we are looking at the potential to have to deal with this question in the next 6 - 9 months ( this is when animal testing will be completed ). Each one of you has to ask yourself if you are willing to sell your stock at $1 - $2 - $3 or whatever when their is such a large potential for the stock in the next 6 - 9 months. I personally think it would be absolutely foolish to look at this stock for just a S.T. run up. You will probably make some good money S.T. but you would be missing the real opportunity here. What would you be willing to sell this technology for ? Think about it. Gwolf